Collplant Biotechnologies Ltd Financials
Collplant Biotechnologies Ltd (CLGN) reported $2.4M in revenue for fiscal year 2025, up 360.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending dominates CollPlant’s economics, while operating cash consumption shrinks equity despite low capital needs.
In FY2025, operating cash flow of-$9.4M nearly matched free cash flow of-$9.4M , showing that the cash deficit comes primarily from running the development program rather than heavy asset reinvestment. Revenue reached$2.4M in FY2025, still far below research and development spending of$8.2M , so commercial activity has not yet absorbed the core investment burden.
The return to a 64.8% gross margin in FY2025 from
Balance-sheet flexibility is narrowing: equity fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Collplant Biotechnologies Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Collplant Biotechnologies Ltd's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 13/100.
Collplant Biotechnologies Ltd's revenue surged 360.4% year-over-year to $2.4M, reflecting rapid business expansion. This strong growth earns a score of 1/100.
Collplant Biotechnologies Ltd has a moderate D/E ratio of 0.77. This balance of debt and equity financing earns a leverage score of 51/100.
With a current ratio of 2.53, Collplant Biotechnologies Ltd holds $2.53 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
Collplant Biotechnologies Ltd's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 5/100.
Collplant Biotechnologies Ltd posts a -188.9% return on equity (ROE), meaning it loses $189 for every $100 of shareholders' equity. This results in a returns score of 13/100. This is down from -123.4% the prior year.
Collplant Biotechnologies Ltd scores -18.18, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.8M) relative to total liabilities ($4.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Collplant Biotechnologies Ltd passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Collplant Biotechnologies Ltd reported a net loss of $11.5M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Collplant Biotechnologies Ltd generated $2.4M in revenue in fiscal year 2025. This represents an increase of 360.4% from the prior year.
Collplant Biotechnologies Ltd's EBITDA was -$10.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 34.8% from the prior year.
Collplant Biotechnologies Ltd reported -$11.5M in net income in fiscal year 2025. This represents an increase of 30.8% from the prior year.
Collplant Biotechnologies Ltd earned -$0.94 per diluted share (EPS) in fiscal year 2025. This represents an increase of 35.2% from the prior year.
Cash & Balance Sheet
Collplant Biotechnologies Ltd recorded an outflow of $9.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 35.2% from the prior year.
Collplant Biotechnologies Ltd held $5.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Collplant Biotechnologies Ltd's gross margin was 64.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Collplant Biotechnologies Ltd's ROE was -188.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 65.6 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Collplant Biotechnologies Ltd invested $8.2M in research and development in fiscal year 2025. This represents a decrease of 22.1% from the prior year.
Collplant Biotechnologies Ltd invested $28K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 94.2% from the prior year.
Not reported for fiscal year 2025.
CLGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $179K | N/A | $249K | N/A | $10.2M | N/A | $66K |
| Cost of Revenue | N/A | $186K | N/A | $536K | N/A | $615K | N/A | $43K |
| Gross Profit | N/A | -$7K | N/A | -$287K | N/A | $9.6M | N/A | $23K |
| R&D Expenses | N/A | $2.0M | N/A | $2.7M | N/A | $2.6M | N/A | $2.6M |
| SG&A Expenses | N/A | $1.2M | N/A | $1.4M | N/A | $1.3M | N/A | $1.6M |
| Operating Income | N/A | -$3.2M | N/A | -$4.4M | N/A | $5.7M | N/A | -$4.2M |
| Net Income | N/A | -$3.3M | N/A | -$4.2M | N/A | $5.8M | N/A | -$4.3M |
| EPS (Diluted) | N/A | $0.28 | N/A | $0.37 | N/A | $0.49 | N/A | -$0.39 |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
CLGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.8M-38.1% | $17.4M-6.8% | $18.7M-29.6% | $26.6M-22.2% | $34.1M-17.9% | $41.6M+10.1% | $37.8M-15.0% | $44.4M |
| Current Assets | $6.7M-46.6% | $12.6M-4.2% | $13.2M-35.2% | $20.3M-27.4% | $28.0M-19.6% | $34.9M+10.1% | $31.7M-17.3% | $38.3M |
| Cash & Equivalents | $5.6M-51.1% | $11.4M-4.0% | $11.9M-37.1% | $18.9M-29.1% | $26.7M+19.7% | $22.3M-24.9% | $29.7M-18.3% | $36.3M |
| Inventory | $573K+3.6% | $553K+25.7% | $440K+0.2% | $439K-38.5% | $714K-54.0% | $1.6M+8.5% | $1.4M+5.5% | $1.4M |
| Accounts Receivable | $1K | N/A | $150K-40.0% | $250K | N/A | N/A | $9K0.0% | $9K |
| Total Liabilities | $4.7M-4.6% | $4.9M-6.0% | $5.2M-10.1% | $5.8M+0.9% | $5.8M+4.6% | $5.5M+0.8% | $5.5M+11.8% | $4.9M |
| Current Liabilities | $2.7M-2.6% | $2.7M-7.7% | $3.0M-8.4% | $3.2M-0.3% | $3.3M+16.9% | $2.8M-10.4% | $3.1M+31.5% | $2.4M |
| Total Equity | $6.1M-51.4% | $12.5M-7.1% | $13.5M-35.0% | $20.7M-26.9% | $28.3M-21.4% | $36.0M+11.6% | $32.3M-18.3% | $39.5M |
| Retained Earnings | -$124.8M-5.7% | -$118.1M-4.2% | -$113.3M-7.8% | -$105.1M-8.7% | -$96.7M-10.3% | -$87.7M+2.3% | -$89.7M-10.8% | -$80.9M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CLGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
CLGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | -3.9% | N/A | -115.3% | N/A | 94.0% | N/A | 34.8% |
| Operating Margin | N/A | -1775.4% | N/A | -1769.5% | N/A | 55.7% | N/A | -6340.9% |
| Net Margin | N/A | -1869.8% | N/A | -1690.8% | N/A | 56.6% | N/A | -6492.4% |
| Return on Equity | N/A | -26.8% | N/A | -20.3% | N/A | 16.0% | N/A | -10.8% |
| Return on Assets | N/A | -19.2% | N/A | -15.8% | N/A | 13.9% | N/A | -9.7% |
| Current Ratio | 2.53-2.1x | 4.60+0.2x | 4.44-1.8x | 6.27-2.3x | 8.62-3.9x | 12.53+2.3x | 10.20-6.0x | 16.21 |
| Debt-to-Equity | 0.77+0.4x | 0.390.0x | 0.39+0.1x | 0.28+0.1x | 0.20+0.1x | 0.150.0x | 0.170.0x | 0.12 |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Similar Companies
Where Collplant Biotechnologies Ltd Ranks
Frequently Asked Questions
What is Collplant Biotechnologies Ltd's annual revenue?
Collplant Biotechnologies Ltd (CLGN) reported $2.4M in total revenue for fiscal year 2025. This represents a 360.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Collplant Biotechnologies Ltd's revenue growing?
Collplant Biotechnologies Ltd (CLGN) revenue grew by 360.4% year-over-year, from $515K to $2.4M in fiscal year 2025.
Is Collplant Biotechnologies Ltd profitable?
No, Collplant Biotechnologies Ltd (CLGN) reported a net income of -$11.5M in fiscal year 2025.
What is Collplant Biotechnologies Ltd's EBITDA?
Collplant Biotechnologies Ltd (CLGN) had EBITDA of -$10.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Collplant Biotechnologies Ltd's gross margin?
Collplant Biotechnologies Ltd (CLGN) had a gross margin of 64.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Collplant Biotechnologies Ltd's return on equity (ROE)?
Collplant Biotechnologies Ltd (CLGN) has a return on equity of -188.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Collplant Biotechnologies Ltd's free cash flow?
Collplant Biotechnologies Ltd (CLGN) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. This represents a 35.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Collplant Biotechnologies Ltd's operating cash flow?
Collplant Biotechnologies Ltd (CLGN) recorded an outflow of $9.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Collplant Biotechnologies Ltd's total assets?
Collplant Biotechnologies Ltd (CLGN) had $10.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Collplant Biotechnologies Ltd's capital expenditures?
Collplant Biotechnologies Ltd (CLGN) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Collplant Biotechnologies Ltd spend on research and development?
Collplant Biotechnologies Ltd (CLGN) invested $8.2M in research and development during fiscal year 2025.
What is Collplant Biotechnologies Ltd's current ratio?
Collplant Biotechnologies Ltd (CLGN) had a current ratio of 2.53 as of fiscal year 2025, which is generally considered healthy.
What is Collplant Biotechnologies Ltd's debt-to-equity ratio?
Collplant Biotechnologies Ltd (CLGN) had a debt-to-equity ratio of 0.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Collplant Biotechnologies Ltd's return on assets (ROA)?
Collplant Biotechnologies Ltd (CLGN) had a return on assets of -106.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Collplant Biotechnologies Ltd's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Collplant Biotechnologies Ltd (CLGN) held $5.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.4M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Collplant Biotechnologies Ltd's Altman Z-Score?
Collplant Biotechnologies Ltd (CLGN) has an Altman Z-Score of -18.18, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Collplant Biotechnologies Ltd's Piotroski F-Score?
Collplant Biotechnologies Ltd (CLGN) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Collplant Biotechnologies Ltd's earnings high quality?
Collplant Biotechnologies Ltd (CLGN) reported a net loss of $11.5M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Collplant Biotechnologies Ltd?
Collplant Biotechnologies Ltd (CLGN) scores 26 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.